KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to $242.5 million.

  • Rigel Pharmaceuticals' Liabilities and Shareholders Equity rose 7396.05% to $242.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $789.2 million, marking a year-over-year increase of 5427.34%. This contributed to the annual value of $164.0 million for FY2024, which is 3988.14% up from last year.
  • Rigel Pharmaceuticals' Liabilities and Shareholders Equity amounted to $242.5 million in Q3 2025, which was up 7396.05% from $206.7 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $242.5 million during Q3 2025, with a 5-year trough of $115.3 million in Q3 2023.
  • Its 5-year average for Liabilities and Shareholders Equity is $155.5 million, with a median of $139.4 million in 2024.
  • Per our database at Business Quant, Rigel Pharmaceuticals' Liabilities and Shareholders Equity plummeted by 3801.72% in 2022 and then soared by 7396.05% in 2025.
  • Rigel Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $167.3 million in 2021, then dropped by 19.75% to $134.3 million in 2022, then decreased by 12.7% to $117.2 million in 2023, then skyrocketed by 39.88% to $164.0 million in 2024, then surged by 47.91% to $242.5 million in 2025.
  • Its last three reported values are $242.5 million in Q3 2025, $206.7 million for Q2 2025, and $176.0 million during Q1 2025.